LY-334370

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H22FN3O
Molecular Weight	351.4173
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1CCC(CC1)C2=CNC3=C2C=C(NC(=O)C4=CC=C(F)C=C4)C=C3

InChI

InChIKey=MDMJLMDBRQXOOI-UHFFFAOYSA-N

InChI=1S/C21H22FN3O/c1-25-10-8-14(9-11-25)19-13-23-20-7-6-17(12-18(19)20)24-21(26)15-2-4-16(22)5-3-15/h2-7,12-14,23H,8-11H2,1H3,(H,24,26)

HIDE SMILES / InChI

Molecular Formula	C21H22FN3O
Molecular Weight	351.4173
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://adisinsight.springer.com/drugs/800008817
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15900510 | https://www.ncbi.nlm.nih.gov/pubmed/9641544

LY-334370 is a selective agonist at the serotonin 1F receptor. Lilly had been conducting phase II clinical testing of this compound in Europe as a potential therapy for migraine headaches. Lilly has now announced that it has discontinued commercial development of LY 334370 as a result of a review of data from an ongoing animal toxicology study. It was reported that the compound causes G-protein activation that is mediated by 5-HT1A receptors.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 1f (5-HT1f) receptor 15 Target ID: CHEMBL1805 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15900510	Agonist 2752		0.446 nM [Kd]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Migraine 107 Sources: http://adisinsight.springer.com/drugs/800008817	Primary		Phase II 1147	Unknown Approved Use Unknown

Doses

Dose	Population	Adverse events
200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11675061	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11675061	Other AEs: Asthenia, Dizziness... Other AEs: Asthenia (27%) Dizziness (35%) Somnolence (23%) Paresthesia (19%) Sources: https://pubmed.ncbi.nlm.nih.gov/11675061

AEs

AE	Significance	Dose	Population
Paresthesia	19%	200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11675061	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11675061
Somnolence	23%	200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11675061	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11675061
Asthenia	27%	200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11675061	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11675061
Dizziness	35%	200 mg single, oral Highest studied dose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/11675061	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11675061

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00AL83	https://www.1pchem.com/search?query=1P00AL83
AChemBlock	Q70200	http://www.achemblock.com/catalogsearch/result/?q=Q70200
Angene	AGN-PC-02ISQ2	http://www.angenechemical.com/productshow/AGN-PC-02ISQ2.html
ApexBio Technology	B7267	https://www.apexbt.com/catalogsearch/result/?q=B7267
Axon MedChem	1612	https://www.axonmedchem.com/product/1612
BLD Pharm	BD559258	http://www.bldpharm.com/search/Search.html?keyword=BD559258
BOC Sciences	182563-08-2	http://www.bocsci.com/description.asp?cas=182563-08-2
Chem Scene	CS-0025021	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0025021
ChemShuttle	113719	https://www.chemshuttle.com/catalogsearch/result/?q=113719
eMolecules	24950869	https://orderbb.emolecules.com/search/#?query=24950869
eMolecules	300123789	https://orderbb.emolecules.com/search/#?query=300123789
eMolecules	36367185	https://orderbb.emolecules.com/search/#?query=36367185
Lab Network	LN00334306	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00334306
Matrix Scientific	147806	http://www.matrixscientific.com/147806.html
mcule	MCULE-5931963296	https://mcule.com/MCULE-5931963296/
mcule	MCULE-6812742236	https://mcule.com/MCULE-6812742236/
MedChem Express	HY-103107	https://www.medchemexpress.com/search.html?q=HY-103107&ft=&fa=&fp=
Molnova	M18144	https://www.molnova.com/en/serch-list.html?keywords=M18144
MolPort	MolPort-023-276-654	https://www.molport.com/shop/molecule-link/MolPort-023-276-654
MolPort	MolPort-035-936-419	https://www.molport.com/shop/molecule-link/MolPort-035-936-419
MuseChem	I007844	https://www.musechem.com/product/I007844.html
MuseChem	I012956	https://www.musechem.com/product/I012956.html
Princeton BioMolecular Research	PBMR221955	http://www.princetonbio.com/order_online?common_id=PBMR221955
ShangHai Biochempartner	BCP29131	http://www.biochempartner.com/search_BCP29131
TargetMol	T4266	https://www.targetmol.com/search?keyword=T4266
Tocris	3079	https://www.tocris.com/search.php?Type=QuickSearch&Value=3079

PubMed

Title	Date	PubMed
Agonism of the 5-hydroxytryptamine 1F receptor promotes mitochondrial biogenesis and recovery from acute kidney injury.	2014-08	24849926
Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.	2012-12	22934751
Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.	2008-06-26	18507369
[3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties.	2005-03	15900510
[3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain.	2005-03	15900511
Crystal forms of LY334370 HCl: isolation, solid-state characterization, and physicochemical properties.	2003-06	12761809
Ligands for the investigation of 5-HT autoreceptor function.	2001-11-15	11750791
Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial.	2001-10-13	11675061
Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370.	1999-12	10668103
G-protein activation at 5-HT1A receptors by the 5-ht1F ligand LY334370 in guinea-pig brain sections and recombinant cell lines.	1998-05	9641544

Patents

Sample Use Guides

In Vivo Use Guide

LY334370 (20, 60, or 200 mg) was given to outpatients with moderate or severe migraine headaches in a double blind, parallel group study

Route of Administration: Oral

In Vitro Use Guide

1–100 nM LY334370 increased carbonylcyanide-p-trifluoromethoxyphenylhydrazone–uncoupled oxygen consumption in renal proximal tubule cells

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:11:26 GMT 2025` Edited by `admin` on `Mon Mar 31 18:11:26 GMT 2025`
Record UNII	5Q7I1WL2UY
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LY-334370

Code

English

BENZAMIDE, 4-FLUORO-N-(3-(1-METHYL-4-PIPERIDINYL)-1H-INDOL-5-YL)-

Preferred Name

English

4-FLUORO-N-(3-(1-METHYLPIPERIDIN-4-YL)-1H-INDOL-5-YL)BENZAMIDE

Systematic Name

English

LY334370

Code

English

Code System Code Type Description

CAS

182563-08-2